Researchers have discovered a novel neurotrophic factor CDNF (Conserved Dopamine Neurotrophic Factor) that was shown to protect and even rescue damaged dopamine neurons in an experimental model of ...
In Parkinson’s disease (PD) dopamine (DA) neurons located in the substantia nigra (SN) degenerate and die. Since all current therapies only treat symptoms, we hope to develop novel disease-modifying ...
Herantis Pharma Plc ("Herantis") announced today the initiation of a non-invasive CDNF development program to broaden the application of CDNF in Parkinson`s disease and potentially other ...
A research group at the University of Helsinki and its partners have found a promising drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). Cerebral dopamine neurotrophic factor ...
Figure: Solution structure of human MANF protein. PDB ID: 2KVD [7]. Cerebral dopamine neurotrophic factor (CDNF) and mesencephalic astrocyte derived neurotrophic factor (MANF) form an evolutionary ...
* HERANTIS PHARMA OYJ - TOPLINE ANALYSIS CONFIRMS POSITIVE SAFETY AND TOLERABILITY OF CDNF IN ADVANCED-STAGE PARKINSON'S DISEASE PATIENTS, WITH ENCOURAGING BIOLOGICAL RESPONSES AS MEASURED BY PET ...
Finnish Medicines Agency Fimea has authorized Herantis Pharma Plc`s ("Herantis") first-in-human clinical study of the company`s investigational product CDNF for the treatment of Parkinson`s disease.
A research group at the University of Helsinki and its partners have found a promising drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). Cerebral dopamine neurotrophic factor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results